🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today, we are announcing a new pre-seed venture fund – Altitude Lab Fund – to support early-stage biotech startups facing the loss of SBIR grants due to recent federal funding policy shifts which have left many biotech founders in limbo. I wrote about why these funds are so

IYKYK 🤣

Beautiful Sunday morning 10k run with the Recursion team in London raising money for Cancer Research UK. We were a small but mighty cohort and brought along our Rare Disease Day zebras for good measure! Thanks team!

NGL, this is a pretty epic crew for Blue Origin to be launching... Jealous.

We just announced our Q4 and FY2024 financial results. It has been a momentous year for Recursion and the TechBio industry, with a number of critical factors now converging to allow us to rapidly accelerate our efforts to transform drug discovery and development. Across

A new #AI education initiative in the State of Utah, developed with NVIDIA, is set to advance the state’s commitment to workforce training and economic growth. nvda.ws/3XEge5w

Founders who were PhD or post-doc in my lab at Berkeley, **largely funded by NSF / DoD grants**, start-up, market cap (collected by OpenAI Deep Research)

Excited to welcome Dr. Namandjé Bumpus & Elaine Sun to Recursion's Board of Directors! 🚀 🔬 Namandjé, former FDA Principal Deputy Commissioner, brings deep regulatory & scientific expertise. 💰 Elaine, COO & CFO at Mammoth Biosciences, adds critical financial &

Today, we announced the first patient dosed in Recursion’s Phase 1 trial of REC-3565 (EXCELERIZE) – a potential best-in-class MALT1 inhibitor – marking an important step forward in our efforts to improve outcomes for patients with B-cell malignancies who currently have

Today, we’re reporting business updates and first quarter 2025 financial results. 🔹 Key updates include: ▪️ Prioritizing our pipeline: We’re delivering on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs

Big moments of focus often follow big bets. Over the last few years, we’ve been running one of the most ambitious experiments in the history of biotechnology: to decode biology with unprecedented scale and precision through the integration of automation, AI, and wet lab science.

IYKYK

Such a delight to continue working with Lina Nilsson as our Chief Platform Officer Recursion where she will steward our Recursion OS, ensuring the machine continues to improve, that it is fully integrated into all we do and that we invest appropriately into the

For over a decade at Recursion, we've been driven by a core belief: truly understanding biology, and ultimately accelerating drug discovery, starts with building the right datasets. Every week we run millions of experiments in our highly automated wet lab to generate this

One of my favorite things when guests visit our headquarters in Salt Lake is to take them for a tour in our labs. Seeing our robots in action, running millions of experiments every week, generating petabytes of data for training AI models (the equivalent of my entire PhD's worth

I recently had a great conversation with David Bearss on the Good Medicine Podcast, reflecting on Recursion's journey over the past 11+ years, the current state of TechBio, and where the industry is headed next. David is a serial entrepreneur and experienced drug hunter who shares my

In my JPM presentation in January, I talked about the work happening at Recursion to help build a virtual cell, spanning the atomistic scale to the protein scale to the pathway scale all the way up to the patient scale. While Recursion is leading the field with in-house

As part of our ongoing commitment to deliver maximal impact from the Recursion 2.0 platform, the maturation of AI tools and ongoing friction in biotech capital markets, today we are updating our tactics at Recursion to continue to deliver on our ambitious strategy. 🔹 Optimized

The current climate in biotech demands incredibly tough choices, and like many, we at Recursion recently faced one of the hardest. If you've been in a leadership seat, you know these decisions carry immense weight – yet they are also essential to achieving your mission.